Status: Not yet recruiting
Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
The purpose of this study is to evaluate the efficacy and safety of APSMNF in the treatment of male androgenetic alopecia.
Participants needed: 336
Trial details
Phase: Phase 3Age: 18-60Biological sex: MaleType: InterventionalSponsor: Apsen Farmaceutica S.A.Updated: Apr 13, 2026Locations: 1
Eligibility criteria
Men aged 18 to 60 years with a clinical diagnosis of androgenetic alopecia ; [+1]
History of allergic reactions to any of the active ingredients or to any of the... [+3]